Curevo Vaccine is a clinical-stage biotechnology company that specializes in developing a new generation of adjuvanted subunit vaccines. These vaccines are designed to enhance the immune response and provide better protection against diseases such as shingles and chickenpox. The use of adjuvants in their vaccine formulations aims to improve the efficacy and safety profiles of the vaccines, making them more effective in generating a robust immune response. This innovative approach positions Curevo at the forefront of vaccine development, focusing on creating more effective solutions for infectious diseases.

The company’s pipeline includes specific products like Amezosvatein, which targets shingles and chickenpox, indicating a focused strategy on addressing prevalent viral infections. By leveraging advanced vaccine technologies, Curevo aims to bring these promising candidates to market, contributing to public health and improving patient outcomes. Their commitment to research and development in the field of immunology underscores their goal of creating better vaccines that can meet the evolving needs of healthcare.

United States

Curevo will combine excellence in protein science and adjuvant technology to speed safe and highly effective vaccines from the bench through clinical development. Curevo will focus on vaccine-preventable illnesses that are common in both the Asian and US markets and for which current vaccine products are not available. Cuervo's goal is to rapidly advance innovative new vaccine candidates from the research laboratory to the clinic by joining forces with the South Korean Mogam Institute for Biomedical Research, GC Pharma, and the Infectious Disease Research Institute based in Seattle, Washington.

Curevo Vaccine

Company Details